EPANED KIT
Clinical safety rating
cautionComprehensive clinical and safety monograph for EPANED KIT (EPANED KIT).
Vitamin B12 (cobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also reduces homocysteine levels.
| Metabolism | Hydroxocobalamin is converted to methylcobalamin and adenosylcobalamin in the liver. It undergoes enterohepatic recycling and is primarily excreted unchanged in bile, with minimal renal excretion. |
| Excretion | Renal: 50-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; minimal respiratory excretion. |
| Half-life | Terminal elimination half-life: 2.4–3.2 hours in healthy adults; prolonged to 5–10 hours in hepatic impairment; clinically relevant for dosing interval adjustment. |
| Protein binding | 90–95% primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3–0.5 L/kg; indicates distribution mainly into extracellular fluid and well-perfused tissues. |
| Bioavailability | Intravenous: 100%; intramuscular: 75–85%; oral: 40–60% (first-pass effect). |
| Onset of Action | Intravenous: 5–10 minutes; intramuscular: 15–30 minutes; oral: 30–60 minutes. |
| Duration of Action | Intravenous: 2–4 hours; intramuscular: 3–6 hours; oral: 4–8 hours; duration may be extended in hepatic dysfunction. |
| Molecular Weight | 406.41 Da (fosphenytoin disodium) |
Intravenous: 0.5-1 mg/kg/dose (max 50 mg/dose) every 6 hours as needed for nausea and vomiting.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR 10-50 mL/min: No adjustment. GFR <10 mL/min: Not recommended due to propylene glycol accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B or C: Maximum 150 mg/day (total daily dose) due to reduced clearance. |
| Pediatric use | Children 2-12 years: 0.5-1 mg/kg/dose (max 25 mg/dose) IV every 6 hours. Infants <2 years: 0.5 mg/kg/dose IV every 6 hours. Not recommended for neonates. |
| Geriatric use | No specific dose adjustment, but consider reduced clearance; use lowest effective dose and monitor for anticholinergic effects. |
| 1st trimester | EPANED KIT contains fosphenytoin, a prodrug of phenytoin. Phenytoin is associated with fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability) and major malformations. Use only if benefit outweighs risk. |
| 2nd trimester | Continued risk of fetal hydantoin syndrome. Monitor for bleeding due to vitamin K deficiency. Use only if clearly needed. |
| 3rd trimester | Risk of neonatal hemorrhage (vitamin K deficiency) and withdrawal symptoms. May cause coagulation defects. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for EPANED KIT (EPANED KIT).
| Placental transfer | Phenytoin readily crosses the placenta, achieving fetal plasma levels approximately 100% of maternal concentrations, indicating extensive placental transfer. |
| Breastfeeding | Fosphenytoin is rapidly converted to phenytoin, which is excreted into breast milk in low concentrations (milk-to-plasma ratio ~0.2-0.4). Doses of phenytoin up to 600 mg/day produce low infant exposure (2-4% of maternal weight-adjusted dose). Monitor infant for drowsiness, irritability, feeding difficulties, and allergic reactions. American Academy of Pediatrics considers phenytoin compatible with breastfeeding. |
| Lactation Rating | L2 (Limited data - probably compatible) or 'Safe' (AAP) |
| Teratogenic Risk | EPANED KIT (hydroxyprogesterone caproate) is a progestin. First trimester: No evidence of increased risk of major birth defects based on clinical studies and postmarketing surveillance, but animal studies with high doses showed some developmental effects. Second and third trimesters: No teratogenic effects; used to reduce risk of preterm birth. Long-term follow-up of exposed children shows no increased rate of congenital anomalies. |
| Fetal Monitoring | Monitor maternal blood pressure, fluid balance, and signs of thromboembolic events. Fetal monitoring includes serial ultrasound for growth, amniotic fluid index, and fetal heart rate. Assess for signs of gestational diabetes. No specific laboratory monitoring required beyond routine prenatal care. |
| Fertility Effects | No known significant effects on fertility. As a progestin, it may inhibit ovulation at high doses, but the low dose in pregnancy use is not intended for contraception. Return to fertility after discontinuation is expected. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to fosphenytoin, phenytoin, other hydantoins, or any componentSinus bradycardiaSinoatrial blockSecond- or third-degree AV blockAdams-Stokes syndromeHistory of prior acute hepatotoxicity attributable to phenytoinConcurrent use of delavirdine
| Precautions | May cause hypokalemia and increased platelet count during initial treatment of pernicious anemia; monitor potassium levels., Avoid in patients with cobalt hypersensitivity (cobalt is a component of hydroxocobalamin)., Not suitable for leber's disease (hereditary optic nerve atrophy) due to risk of optic atrophy., May interact with nitrous oxide (inactivates cobalamin) and chloramphenicol (antagonizes hematologic response). |
| Food/Dietary | No specific food interactions with epinephrine. Diphenhydramine may be taken with or without food. Avoid alcohol while taking diphenhydramine due to additive sedative effects. Patients with certain food allergies (e.g., peanut, egg) should ensure the device components are free of allergens; EPANED KIT contains no known food allergens. |
| Clinical Pearls | EPANED KIT contains epinephrine (for anaphylaxis) and diphenhydramine (for allergic symptoms). Epinephrine is the first-line treatment for anaphylaxis; administer intramuscularly in the anterolateral thigh. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Monitor for rebound anaphylaxis and delayed biphasic reactions. The antihistamine component may cause sedation. |
| Patient Advice | Use the epinephrine auto-injector immediately at the first sign of a severe allergic reaction, even if you are unsure. · Inject into the outer thigh, through clothing if necessary. Do not inject into a vein or buttock. · Seek emergency medical help immediately after using the device. The antihistamine does not replace epinephrine. · Avoid activities requiring alertness until you know how the antihistamine affects you; it may cause drowsiness. · Store at room temperature, protect from light and freezing. Check expiration dates regularly. |
Loading safety data…